Black Rose Industries Ltd
BLACKROSEBlack Rose Industries Ltd is coiled. The quarters are improving, yet the P/E sits at the 8th percentile of its own 10-year range — the business is moving before the market.
Biggest watch item: the price is already 7 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (7 weeks in) while the P/E sits at the 8th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +150.0% year on year, and 77% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Black Rose Industries Ltd trades at ₹113, in a confirmed uptrend and 7 weeks into that stage. That is +15.8% against its own 200-day average. It sits at 64% of a 52-week range of ₹90 to ₹126. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹113 it trades +15.8% versus its 200-day average and sits at 64% of its 52-week range (₹90–₹126).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +25% while the NIFTY 500 moved +5% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Black Rose Industries Ltd trades at 20.1× P/E, near the bottom of its own range — cheaper only 8% of the time. Its long-run median P/E is 32.2×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 20.1× is near the bottom of its own range — cheaper only 8% of the time, against a long-run median of 32.2× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Black Rose Industries Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −20.0% at the trough to +150.0%, a 2-quarter improving streak (single-quarter readings), ROCE lifting at 19.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −17.4% | −9.1% | −3.2% | +6.2% |
| Profit | +4.8% | +40.1% | −4.0% | +27.1% |
| EPS | +7.1% | +41.6% | −3.9% | +30.0% |
4-Factor Sector Score
64.2/100 — rank 2 of 28 in Speciality Chemicals · 72% evidence confidence
Black Rose Industries Ltd scores 64.2 out of 100 against the 28 companies it is compared with in Speciality Chemicals, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.3 + 16.9 + 13.8 + 11.2 = 64.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Black Rose Industries Ltd reported ₹89.0 Cr of revenue in the Jun 26 quarter, +48.3% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 6.2% a year. The last full year, FY26, came in at ₹323 Cr. The last four reported quarters add to ₹352 Cr.
FY26 revenue came in at ₹323 Cr (−17.4% on the year), capping 10 years at 6.2% compound. The latest quarter (Jun 26) printed ₹89.0 Cr, +48.3% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +12.3% growth against the decade's 6.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.6% over the last 4 quarters against −5.1%/yr over the last 8 — accelerating; TTM profit +28.6% vs +10.8%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Black Rose Industries Ltd's operating margin is 16.0% in the Jun 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 3.3% to 11.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 16.0%, +6.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 3.3%–11.0%.
Why the margin moved: operating margin went +6.4 pp year on year while gross margin went +9.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Black Rose Industries Ltd earned ₹10.0 Cr of net profit in the Jun 26 quarter, +150.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹22.0 Cr. The 10-year compound rate is 27.1%. That is 11.2% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr.
Jun 26 profit was ₹10.0 Cr, +150.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹22.0 Cr (+4.8%), and the 10-year compound rate is 27.1%.
Why profit moved: revenue contributed +48.3% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +36.7% vs revenue +12.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 77% of Black Rose Industries Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹45.0 Cr of operating cash against ₹22.0 Cr of profit. After ₹8.0 Cr of capital spending, ₹37.0 Cr was left as free cash.
FY26: operating cash of ₹45.0 Cr against reported profit of ₹22.0 Cr, leaving free cash of ₹37.0 Cr after ₹8.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 77% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 77%: the cash cycle stretched 51 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: conversion is below par and the cash cycle has stretched 51 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Black Rose Industries Ltd's cash conversion cycle runs 112 days in FY26, up from 61 days in FY21. Capital spending ran ₹14.0 Cr over the last 3 years. At FY26 sales of ₹323 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹99.0 Cr sits inside the business at any moment.
FY26: debtors at 79 days, inventory at 69 days — roughly 2.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 112 days, looser than FY21's 61.
The full loop: cash goes out to suppliers and production on day 0; stock waits 69 days to sell; customers pay about 79 days after that; and suppliers themselves are paid at 36 days — netting out to the 112-day cycle.
In money terms: at FY26 sales of ₹323 Cr, each day of the cycle holds about ₹0.9 Cr — so the 112-day loop keeps roughly ₹99.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹14.0 Cr over the last 3 fiscal years against ₹10.0 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Black Rose Industries Ltd earns a ROCE of 19% in FY26. That is up from a trough of 8% in FY15. Return on invested capital clears the cost of that capital by +3.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 6.8% net margin on 1.55× asset turns.
FY26 ROCE is 19%, recovered from a FY15 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 6.8% net margin × 1.55× asset turns × 1.23× balance-sheet leverage ≈ 13.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 15.0% − 12.0% = a +3.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Black Rose Industries Ltd carries ₹1.0 Cr of borrowings against ₹169 Cr of equity in FY26, a debt-to-equity of 0.01. Operating profit covers the interest bill 33×. Over 5 years borrowings went from ₹17.0 Cr to ₹1.0 Cr. Capital spending ran ₹14.0 Cr across the last 3 of those years.
FY26: borrowings of ₹1.0 Cr against equity of ₹169 Cr — a debt-to-equity of 0.01. Operating profit covers the interest bill 33×. Over 5 years borrowings went from ₹17.0 Cr to ₹1.0 Cr while capital spending ran ₹14.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Black Rose Industries Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 75.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +0.2 points over 8 quarters to 0.2%; Promoters: +0.0 points over 8 quarters to 75.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Black Rose Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sunshield Chemicals Ltd530845 | 70.0/100Favorable setup72% evidence | BREAKING OUT | 28.4/35 Revenue 20.5% · PAT 100% · OPM change 5 pp 83% evidence | 16.1/25 ROCE 19.9% · OPM 15% 76% evidence | 11.1/20 P/E 36× · PEG — 50% evidence | 14.4/20 RS sector 2.6% · RS bench 23.4% · 1Y 28.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 28.4 + 16.1 + 11.1 + 14.4 = 70 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Black Rose Industries Ltdthis pageBLACKROSE | 64.2/100Mixed-positive evidence72% evidence | TURNING | 22.3/35 Revenue 8.6% · PAT 28.6% · OPM change 6 pp 95% evidence | 16.9/25 ROCE 18.9% · OPM 16% 95% evidence | 13.8/20 P/E 20.1× · PEG — 50% evidence | 11.2/20 RS sector — · RS bench 14.5% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 22.3 + 16.9 + 13.8 + 11.2 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Pidilite Industries LtdPIDILITIND | 64.1/100Mixed-positive evidence94% evidence | TURNING | 22.0/35 Revenue 14.1% · PAT 21.5% · OPM change 1 pp 100% evidence | 20.1/25 ROCE 31% · OPM 26% 100% evidence | 7.4/20 P/E 63.8× · PEG 3.8 100% evidence | 14.6/20 RS sector 5.5% · RS bench 9.2% · 1Y 16.1%7 of 10 weeks ahead 70% evidence |
| Exact sum: 22 + 20.1 + 7.4 + 14.6 = 64.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Privi Speciality Chemicals LtdPRIVISCL | 63.5/100Mixed-positive evidence75% evidence | FADING | 25.1/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.8/25 ROCE 22.3% · OPM 23% 76% evidence | 9.4/20 P/E 40.7× · PEG — 15% evidence | 11.2/20 RS sector 0.3% · RS bench 17.9% · 1Y 48.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 25.1 + 17.8 + 9.4 + 11.2 = 63.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Vikram Thermo (India) Ltd530477 | 63.1/100Mixed-positive evidence63% evidence | BREAKING OUT | 23.2/35 Revenue 7% · PAT 100% · OPM change 7.1 pp 83% evidence | 19.2/25 ROCE 36.4% · OPM 31.7% 76% evidence | 8.7/20 P/E 20.7× · PEG — 50% evidence | 12.0/20 RS sector — · RS bench 42.2% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 23.2 + 19.2 + 8.7 + 12 = 63.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 6Yasho Industries LtdYASHO | 62.6/100Mixed-positive evidence87% evidence | BREAKING OUT | 29.4/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.4/25 ROCE 8.9% · OPM 24% 100% evidence | 12.0/20 P/E 86.8× · PEG 1.15 65% evidence | 12.8/20 RS sector -2% · RS bench 118.2% · 1Y 127.4%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.4 + 8.4 + 12 + 12.8 = 62.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tatva Chintan Pharma Chem LtdTATVA | 60.2/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.7/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.4/25 ROCE 7.1% · OPM 19% 100% evidence | 4.8/20 P/E 76.7× · PEG 5.63 65% evidence | 18.3/20 RS sector 12.9% · RS bench 32.7% · 1Y 54.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 6.4 + 4.8 + 18.3 = 60.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Panama Petrochem LtdPANAMAPET | 58.0/100Mixed-positive evidence90% evidence | BREAKING OUT | 17.7/35 Revenue 9.7% · PAT 14.5% · OPM change 2 pp 88% evidence | 13.3/25 ROCE 19.2% · OPM 11% 100% evidence | 15.7/20 P/E 14.4× · PEG 0.55 100% evidence | 11.3/20 RS sector -5.5% · RS bench 55.4% · 1Y 43.7%11 of 11 weeks ahead 70% evidence |
| Exact sum: 17.7 + 13.3 + 15.7 + 11.3 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Aether Industries LtdAETHER | 57.0/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.7/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.4/25 ROCE 11.9% · OPM 31% 100% evidence | 4.1/20 P/E 88× · PEG 8.9 100% evidence | 17.8/20 RS sector 30.1% · RS bench 52.6% · 1Y 111.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 10.4 + 4.1 + 17.8 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Kronox Lab Sciences LtdKRONOX | 57.0/100Mixed-positive evidence61% evidence | 13.6/35 Revenue 1% · PAT 8.2% · OPM change 6.8 pp 83% evidence | 21.4/25 ROCE 36% · OPM 36.4% 95% evidence | 10.9/20 P/E 21.9× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 12.8% · 1Y — 25% evidence | |
| Exact sum: 13.6 + 21.4 + 10.9 + 11.1 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Alkyl Amines Chemicals LtdALKYLAMINE | 56.8/100Mixed-positive evidence73% evidence | TURNING | 20.6/35 Revenue 17.4% · PAT 100% · OPM change -0.1 pp 71% evidence | 18.6/25 ROCE 41.3% · OPM 14.5% 95% evidence | 9.2/20 P/E 51.1× · PEG — 50% evidence | 8.4/20 RS sector -14.3% · RS bench 8.4% · 1Y -19.1%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 18.6 + 9.2 + 8.4 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Aarti Industries LtdAARTIIND | 54.9/100Mixed-positive evidence100% evidence | FADING | 28.1/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.4/25 ROCE 6.8% · OPM 16% 100% evidence | 7.0/20 P/E 34.9× · PEG 2.05 100% evidence | 11.4/20 RS sector -0.9% · RS bench 16.5% · 1Y 23.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 8.4 + 7 + 11.4 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Vinati Organics LtdVINATIORGA | 50.2/100Mixed-positive evidence76% evidence | ASLEEP | 12.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.4/25 ROCE 19.8% · OPM 24% 76% evidence | 13.4/20 P/E 30.6× · PEG — 50% evidence | 7.2/20 RS sector -3.8% · RS bench -13.2% · 1Y -26.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.2 + 17.4 + 13.4 + 7.2 = 50.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 14Chemcon Speciality Chemicals LtdCHEMCON | 48.3/100Mixed-negative evidence81% evidence | TURNING | 21.4/35 Revenue 16.7% · PAT 12% · OPM change 8 pp 95% evidence | 10.7/25 ROCE 6.4% · OPM 23% 95% evidence | 11.6/20 P/E 24.7× · PEG — 50% evidence | 4.6/20 RS sector -21.5% · RS bench -5.3% · 1Y -18.2%9 of 10 weeks ahead 70% evidence |
| Exact sum: 21.4 + 10.7 + 11.6 + 4.6 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Fineotex Chemical LtdFCL | 47.8/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.1/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 12.7/25 ROCE 18.3% · OPM 16% 100% evidence | 3.3/20 P/E 39.6× · PEG 4.19 100% evidence | 12.7/20 RS sector -2% · RS bench 47% · 1Y 63.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 19.1 + 12.7 + 3.3 + 12.7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16DMCC Speciality Chemicals LtdDMCC | 47.4/100Mixed-negative evidence76% evidence | ASLEEP | 20.7/35 Revenue 34.8% · PAT 27% · OPM change -2.1 pp 83% evidence | 11.1/25 ROCE 15.3% · OPM 10% 95% evidence | 10.6/20 P/E 25.3× · PEG — 15% evidence | 5.0/20 RS sector -13.7% · RS bench 1.2% · 1Y -8.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 11.1 + 10.6 + 5 = 47.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Platinum Industries LtdPLATIND | 46.1/100Mixed-negative evidence70% evidence | ASLEEP | 16.6/35 Revenue 14.5% · PAT 0% · OPM change 4 pp 83% evidence | 12.3/25 ROCE 15.7% · OPM 12% 95% evidence | 10.8/20 P/E 23.6× · PEG — 15% evidence | 6.4/20 RS sector -10.3% · RS bench -10% · 1Y -18.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 12.3 + 10.8 + 6.4 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Neogen Chemicals LtdNEOGEN | 42.5/100Mixed-negative evidence90% evidence | LEADER | 15.4/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.8/25 ROCE 6.5% · OPM 19% 100% evidence | 5.1/20 P/E 156× · PEG — 50% evidence | 15.2/20 RS sector 12.9% · RS bench 31.6% · 1Y 32%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 6.8 + 5.1 + 15.2 = 42.5 · Decision use: Price leads the evidence: RS versus the benchmark is 31.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Galaxy Surfactants LtdGALAXYSURF | 41.6/100Mixed-negative evidence90% evidence | TURNING | 12.5/35 Revenue 24.2% · PAT -13.1% · OPM change -2 pp 88% evidence | 12.8/25 ROCE 13.5% · OPM 9% 100% evidence | 8.4/20 P/E 26.4× · PEG 4.39 100% evidence | 7.9/20 RS sector -11.9% · RS bench 1.3% · 1Y -22.2%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.5 + 12.8 + 8.4 + 7.9 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Anupam Rasayan India LtdANURAS | 41.4/100Mixed-negative evidence78% evidence | ASLEEP | 20.6/35 Revenue 64.5% · PAT 38.8% · OPM change -7 pp 83% evidence | 10.2/25 ROCE 7.4% · OPM 22% 76% evidence | 8.0/20 P/E 81.3× · PEG — 50% evidence | 2.6/20 RS sector -18.9% · RS bench -4.2% · 1Y 6.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 10.2 + 8 + 2.6 = 41.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Amal Ltd506597 | 41.4/100Mixed-negative evidence69% evidence | TURNING | 7.9/35 Revenue 79% · PAT -23.1% · OPM change -7 pp 95% evidence | 16.3/25 ROCE 26% · OPM 18% 76% evidence | 10.0/20 P/E 31.1× · PEG — 15% evidence | 7.2/20 RS sector -23.2% · RS bench 10.7% · 1Y -23.9%7 of 10 weeks ahead 70% evidence |
| Exact sum: 7.9 + 16.3 + 10 + 7.2 = 41.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Vishnu Chemicals LtdVISHNU | 40.8/100Mixed-negative evidence100% evidence | FADING | 15.6/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.3/25 ROCE 16.3% · OPM 15% 100% evidence | 6.2/20 P/E 26.4× · PEG 2.82 100% evidence | 7.7/20 RS sector -9% · RS bench 6.9% · 1Y 8.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 11.3 + 6.2 + 7.7 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Amines & Plasticizers LtdAMNPLST | 38.7/100Mixed-negative evidence77% evidence | TURNING | 9.5/35 Revenue -13.8% · PAT -14.3% · OPM change 2 pp 83% evidence | 14.7/25 ROCE 16.7% · OPM 15% 95% evidence | 8.5/20 P/E 29.3× · PEG — 50% evidence | 6.0/20 RS sector -19.2% · RS bench -0.8% · 1Y -14.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.5 + 14.7 + 8.5 + 6 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Transpek Industry LtdTRANSPEK | 37.3/100Mixed-negative evidence81% evidence | ASLEEP | 7.7/35 Revenue -4.4% · PAT -6.3% · OPM change -2.3 pp 95% evidence | 9.0/25 ROCE 8.3% · OPM 13.3% 95% evidence | 13.6/20 P/E 18.1× · PEG — 50% evidence | 7.0/20 RS sector -19.5% · RS bench 4.3% · 1Y -22%3 of 10 weeks ahead 70% evidence |
| Exact sum: 7.7 + 9 + 13.6 + 7 = 37.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 25Grauer & Weil (India) LtdGRAUWEIL | 36.8/100Mixed-negative evidence100% evidence | ASLEEP | 8.8/35 Revenue 4.9% · PAT 4.4% · OPM change -5 pp 100% evidence | 16.4/25 ROCE 21.4% · OPM 16% 100% evidence | 7.8/20 P/E 19.8× · PEG 4.01 100% evidence | 3.8/20 RS sector -23.5% · RS bench -10.2% · 1Y -27.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 8.8 + 16.4 + 7.8 + 3.8 = 36.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Paushak LtdPAUSHAKLTD | 36.6/100Mixed-negative evidence81% evidence | BREAKING OUT | 11.9/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 9.8/25 ROCE 8.3% · OPM 31% 95% evidence | 7.9/20 P/E 41.1× · PEG — 50% evidence | 7.0/20 RS sector -27.3% · RS bench 19.3% · 1Y 4.1%7 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.8 + 7.9 + 7 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Clean Science & Technology LtdCLEAN | 34.1/100Adverse evidence94% evidence | ASLEEP | 4.7/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 17.6/25 ROCE 20.6% · OPM 36% 100% evidence | 8.3/20 P/E 36.3× · PEG 6.24 100% evidence | 3.5/20 RS sector -24.1% · RS bench -11.3% · 1Y -34.1%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.7 + 17.6 + 8.3 + 3.5 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Thirumalai Chemicals LtdTIRUMALCHM | 29.1/100Adverse evidence63% evidence | ASLEEP | 13.2/35 Revenue -5.8% · PAT -36.9% · OPM change 12 pp 71% evidence | 1.0/25 ROCE -3.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.9/20 RS sector -15.7% · RS bench -25.7% · 1Y -42.4%1 of 10 weeks ahead 70% evidence |
| Exact sum: 13.2 + 1 + 10 + 4.9 = 29.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Black Rose Industries Ltd's share price today?
Black Rose Industries Ltd trades at ₹113. The company is valued at ₹576 Cr. The stock sits at 64% of its 52-week range of ₹90–₹126, +15.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 7 weeks in. — as of 7 August 2026.
What were Black Rose Industries Ltd's latest quarterly results?
Black Rose Industries Ltd reported revenue of ₹89.0 Cr and net profit of ₹10.0 Cr for the Jun 26 quarter. Revenue rose 48.3% and profit rose 150.0% year on year. Earnings per share were ₹2.04. The operating margin was 16.0%, 6.0 pp higher than a year earlier. — as of 7 August 2026.
What is Black Rose Industries Ltd's revenue?
Black Rose Industries Ltd reported revenue of ₹89.0 Cr in the Jun 26 quarter, +48.3% year on year. For the full FY26 fiscal year, revenue was ₹323 Cr (−17.4%). Over the last 10 years revenue compounded at 6.2% a year. — as of 7 August 2026.
What is Black Rose Industries Ltd's profit?
Black Rose Industries Ltd earned ₹10.0 Cr of net profit in the Jun 26 quarter, +150.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹22.0 Cr. The operating margin ran 16.0% in the latest quarter. — as of 7 August 2026.
What is Black Rose Industries Ltd's market cap?
Black Rose Industries Ltd's market capitalisation is ₹576 Cr at a share price of ₹113. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 7 August 2026.
What is Black Rose Industries Ltd's P/E ratio?
Black Rose Industries Ltd trades at a P/E of 20.1×, at the 8th percentile of its own 10-year range, against a long-run median of 32.2×. This is a comparison with the stock's own history, not a value call — as of 7 August 2026.
Does Black Rose Industries Ltd pay a dividend?
Yes — Black Rose Industries Ltd's dividend payout was 28% of profit in FY26, and it recorded a payout in 10 of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 7 August 2026.
Is Black Rose Industries Ltd overvalued?
On its own history, Black Rose Industries Ltd looks cheap against its own history: its P/E of 20.1× has been cheaper only 8% of the time in 10 years (long-run median 32.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 7 August 2026.
Is Black Rose Industries Ltd growing?
Yes — Black Rose Industries Ltd is growing: latest-quarter revenue +48.3% year on year, profit +150.0%, and the margin +6.0 pp at 16.0%. The 10-year compound rates are 6.2% (revenue) and 27.1% (profit). The earnings engine currently reads: improving — as of 7 August 2026.
How is Black Rose Industries Ltd performing?
Black Rose Industries Ltd is in a confirmed uptrend, 7 weeks in. Its latest quarter's revenue rose 48.3% and profit rose 150.0% year on year. This describes what the data did, not a rating. — as of 7 August 2026.
What stage is Black Rose Industries Ltd in?
Turning around — profit growth swung from −20.0% at the trough to +150.0%, a 2-quarter improving streak (single-quarter readings), ROCE lifting at 19.0%. The read comes from the last 12 quarters of growth (revenue growth +48.3% latest, profit growth +150.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 7 August 2026.
Is Black Rose Industries Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 7 of stage 2), trading +15.8% versus its 200-day average and at 64% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 7 August 2026.
Will Black Rose Industries Ltd's share price go up?
This page publishes no price forecast for Black Rose Industries Ltd. What it measures instead: the share price is ₹113, the price is in a confirmed uptrend 7 weeks in. Its P/E of 20.1× sits at the 8th percentile of its own 10-year range. — as of 7 August 2026.
Who owns Black Rose Industries Ltd?
Promoters hold 75.0% of Black Rose Industries Ltd, foreign institutions null%, domestic institutions 0.2% and the public 24.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 7 August 2026.
Does Black Rose Industries Ltd have too much debt?
No — Black Rose Industries Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 33×. FY26 borrowings were ₹1.0 Cr against equity of ₹169 Cr. The returns on this page are earned, not borrowed — as of 7 August 2026.
What is Black Rose Industries Ltd's capex?
Black Rose Industries Ltd spent ₹14.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹8.0 Cr, with ₹2.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 7 August 2026.
What is Black Rose Industries Ltd's cash flow?
Black Rose Industries Ltd generated ₹45.0 Cr of operating cash flow in FY26 and ₹37.0 Cr of free cash flow after ₹8.0 Cr of capital spending. Reported profit that year was ₹22.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 7 August 2026.
Is Black Rose Industries Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 77% of Black Rose Industries Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹45.0 Cr against reported profit of ₹22.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 7 August 2026.
Where is Black Rose Industries Ltd in its business cycle?
Black Rose Industries Ltd's FY26 operating margin was 10.0%, against a 12-year band of 3.3%–11.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 7 August 2026.
What could break the Black Rose Industries Ltd story?
Biggest watch item: the price is already 7 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 7 August 2026.
Is Black Rose Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Black Rose Industries Ltd is coiled. The quarters are improving, yet the P/E sits at the 8th percentile of its own 10-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 7 August 2026.